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T here is a complex relationship between higher bloodpressure, chronic kidney disease (CKD), and the risk of
stroke. Higher blood pressure is associated with a higher risk
of incident ischemic stroke and more strongly with a higher
risk of incident hemorrhagic stroke.1 Although patients with
CKD are at a higher risk of stroke, there is not a consistent
monotonic relationship between higher blood pressure and
higher risk of cardiovascular diseases in patients with CKD;
indeed, low or normal blood pressures have been associated
with a higher risk of incident cardiovascular diseases in some
studies. This relationship may be causal, but also could be
explained by reverse causality.2
Patients with CKD seem to be at particularly high risk of
stroke. There is an inverse linear relationship between
glomerular ﬁltration rate and the risk of stroke, with an
7% increased relative risk of stroke for every 10–mL/min
per 1.73 m2 decrease in glomerular ﬁltration rate, which
seems consistent across major stroke subtypes.3
In addition, it has been hypothesized that strokes caused
by cerebral small-vessel disease (“lacunar strokes”) are part
of a multisystem small-vessel disorder that affects both the
cerebral and the renal circulations. At younger ages, there are
associations between renal impairment and cerebral white
matter hyperintensities and other markers of cerebral small-
vessel disease, although whether this is a manifestation of
risk factors common to stroke and CKD (chieﬂy hypertension)
or other mechanisms is uncertain.4–6
For these reasons, the effect of intensive blood pressure
reduction on stroke incidence in patients with CKD is of
particular interest for clinicians and epidemiologists.
In this issue of the Journal of the American Heart
Association (JAHA), Agarwal and colleagues7 present a
secondary analysis of data from the SPS3 (Secondary
Prevention of Small Subcortical Strokes) trial, reporting the
effect of intensive blood pressure reduction in patients with
recent lacunar stroke with and without CKD (deﬁning CKD as
estimated glomerular ﬁltration rate <60 mL/min per
1.73 m2).8 The SPS3 trial was a factorial trial that randomly
allocated patients with a recent magnetic resonance imaging–
deﬁned lacunar stroke to a systolic blood pressure target of
<130 mm Hg versus 130 to 149 mm Hg; and to aspirin
versus aspirin and clopidogrel. An important blood pressure
difference was achieved between groups at 1 year (ie, an 11–
mm Hg difference in systolic blood pressure). With more
intense blood pressure lowering, a modest but nonsigniﬁcant
reduction in incidence of all stroke, the primary outcome, was
observed (hazard ratio, 0.84; 95% CI, 0.64–1.03).
In this secondary report of the SPS3 trial, patients with
CKD had a higher risk of recurrent stroke, as expected.
However, there was no qualitative or statistical evidence of a
difference in the formally neutral effect of intensive blood
pressure lowering on death, stroke, myocardial infarction, or
intracranial hemorrhage between patients with CKD and
patients without CKD.
This is consistentwith the results of theSPRINT (Systolic Blood
Pressure Intervention Trial), which did not demonstrate a modi-
ﬁcation in the beneﬁcial effect of intensive versus less intensive
blood pressure lowering on cardiovascular outcomes in patients
with and without CKD.9 In SPRINT, intensive blood pressure
lowering was also not associated with a lower quality of life. Prior
neutral trials of intensive blood pressure lowering in patients with
CKDmayhave included too fewparticipants todetect anypositive
effects on myocardial infarction or stroke.10,11
Therefore, the present study does not support different
blood pressure targets for patients with lacunar stroke with
and without CKD. This is of relevance for physicians looking
after patients with recent stroke. For physicians looking after
patients with CKD, further trials of intense BP lowering
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targeting this group have been suggested to dispel remaining
clinical uncertainties about the balance between potential
harms of blood pressure lowering, particularly to the kidney,
and the potential beneﬁts of blood pressure lowering,
reducing incidence of myocardial infarction, stroke, and
progression of renal disease.2
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